GlassScriptPhysician profile
Nirmal Basaula
NPI 1861970295
$1,156.17
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $422 · 2021: $287.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.46 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $122.10 | 2019-2021 | |
| Pfizer INC. | $101.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $92.89 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.36 | 2019-2021 | |
| Biogen, INC. | $66.46 | 2019-2021 | |
| Novo Nordisk INC | $60.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.77 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $47.26 | 2019 | |
| Glaxosmithkline, LLC. | $45.80 | 2020-2021 | |
| Gilead Sciences, INC. | $43.57 | 2020 | |
| Jazz Pharmaceuticals INC. | $39.92 | 2019-2020 | |
| Shire North American Group INC | $38.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.44 | 2019 | |
| Allergan, INC. | $24.95 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.18 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.34 | 2019 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmal Basaula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.